Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Clarity Pharmaceuticals Ltd

Healthcare AU CU6

2.31AUD
0.00(0%)

Last update at 2026-06-04T06:10:00Z

Day Range

2.252.35
LowHigh

52 Week Range

1.845.87
LowHigh

Fundamentals

  • Previous Close 2.31
  • Market Cap904.59M
  • Volume1308191
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-95.70922M
  • Revenue TTM10.58M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 10.58M
  • Diluted EPS TTM-0.28

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -63.87893M -42.02928M -24.49925M -23.73695M -10.22137M
Minority interest - - - - -
Net income -64.29543M -42.32443M -24.60245M -23.75458M -10.22137M
Selling general administrative 11.51M 10.35M 4.71M 9.07M 3.82M
Selling and marketing expenses 0.17M 0.17M - - -
Gross profit 9.46M 11.51M - - -
Reconciled depreciation 0.19M 0.15M 0.10M 0.05M -
Ebit -69.09403M -44.80066M -26.36351M -30.29097M -10.31330M
Ebitda -68.90894M -44.64759M -36.06355M -30.24472M -
Depreciation and amortization 0.19M 0.15M - 0.05M -
Non operating income net other - - - - -
Operating income -69.09403M -44.80066M -24.49924M -30.29097M -10.22132M
Other operating expenses 78.56M 56.31M - 30.29M -
Interest expense - - - 0.00000M 0.00000M
Tax provision 0.42M 0.30M 0.10M 0.02M 0.00000M
Interest income 4.76M 2.77M 1.86M 0.10M 0.00005M
Net interest income 4.76M 2.77M 1.86M 0.10M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.42M 0.30M 0.10M 0.02M -
Total revenue 9.46M 11.51M 11.66M 6.55M 3.29M
Total operating expenses 78.56M 56.31M - 30.29M -
Cost of revenue - 0.15M - - -
Total other income expense net 5.22M 2.77M 9.80M 6.46M -
Discontinued operations - - - - -
Net income from continuing ops -64.29543M -42.32443M -24.60245M -23.75458M -
Net income applicable to common shares -64.29544M -42.32443M -24.60245M -23.75458M -10.22137M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 101.17M 154.63M 76.90M 99.82M 22.61M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 4.92M - - -
Total liab 10.94M 8.33M 7.72M 7.59M 2.34M
Total stockholder equity 90.23M 146.30M 69.18M 92.24M 20.28M
Deferred long term liab - - - - -
Other current liab - 6.00M 0.48M 4.66M 0.84M
Common stock - 249.45M 132.82M 132.12M 44.90M
Capital stock 255.89M - 132.82M 132.12M -
Retained earnings -176.99413M -112.69870M -70.37427M -45.79569M -28.84960M
Other liab - - 0.18M 0.08M 0.08M
Good will - - - - -
Other assets - - 0.01M 0.01M 0.01M
Cash 47.68M 136.51M 5.97M 55.34M 8.44M
Cash and equivalents - - 25.24M 25.00M -
Total current liabilities 10.38M 8.09M 7.54M 7.51M 2.25M
Current deferred revenue - - - - -
Net debt - -136.50566M - -55.33633M -
Short term debt - - 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - 6.73M 5.92M 4.22M
Property plant equipment - - 0.21M 0.26M 0.09M
Total current assets 100.61M 154.06M 76.68M 99.55M 22.51M
Long term investments 0.01M - 0.01M 0.01M -
Net tangible assets - - 69.18M 92.24M 20.28M
Short term investments 36.43M - 33.80M 37.00M 10.50M
Net receivables - 12.63M 10.00M 6.66M 3.37M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 3.21M 2.08M 2.85M 2.85M 0.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 9.55M - 5.92M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.01M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.57M 0.57M 0.22M 0.27M -
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 51.99M -55.30783M 3.20M -26.50036M -9.50000M
Change to liabilities - - 0.02M 4.93M 1.04M
Total cashflows from investing activities 51.99M -55.30783M 3.15M -26.71351M -9.56031M
Net borrowings - - - - -
Total cash from financing activities 2.21M 115.21M 0.23M 86.93M 20.41M
Change to operating activities - - -0.92263M -0.01123M 0.13M
Net income -64.29543M -42.32443M -24.60245M -23.75458M -10.22137M
Change in cash -0.21651M 16.69M -24.12324M 46.90M 3.17M
Begin period cash flow 47.90M 31.21M 55.34M 8.44M -
End period cash flow 47.68M 47.90M 31.21M 55.34M 8.44M
Total cash from operating activities -54.76902M -43.23710M -27.49996M -13.31392M -7.67708M
Issuance of capital stock 2.40M 121.84M 0.18M 92.40M -
Depreciation - 0.15M 0.10M 0.05M 0.02M
Other cashflows from investing activities 52.17M -54.80383M 3.20M -26.50037M -9.50000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 2.54M -2.63248M -3.34464M -3.28566M -0.71229M
Sale purchase of stock -0.19339M -6.64764M 0.24M -5.60315M 21.10M
Other cashflows from financing activities -0.19339M 0.02M -0.01275M 0.13M -0.68122M
Change to netincome - - 1.25M 8.77M 2.07M
Capital expenditures 0.18M 0.50M 0.05M 0.21M 0.06M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.22M -5.50069M 8.31M 3.34M 2.56M
Stock based compensation - 4.17M - - -
Other non cash items -57.98577M 4.59M - - -
Free cash flow -54.95177M -43.74111M -27.54652M -0.21315M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CU6
Clarity Pharmaceuticals Ltd		 - -% 2.31 - - 85.50 4.17 -0.7791
CSL
CSL Ltd		 0.35 0.38% 92.59 11.33 14.35 3.03 1.83 2.86 8.58
TLX
TELIX Pharmaceuticals Ltd		 0.69 5.66% 12.89 - 2500.00 5.49 7.94 4.51 103.05
MSB
Mesoblast Ltd		 - -% 2.02 - 454.55 40.14 3.31 30.21 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.06 0.44% 13.53 60.00 55.25 27.00 5.17 22.51 66.05

Reports Covered

Stock Research & News

View All

Profile

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd

National Innovation Centre, Sydney, NSW, Australia, 2015

Key Executives

Name Title Year Born
Dr. Alan John Taylor Ph.D. Exec. Chairman NA
Dr. Colin David Biggin Ph.D. MD, CEO & Exec. Director NA
Mr. David K. Green BEc., CA Chief Financial Officer NA
Mr. Robert Vickery Company Sec. NA
Dr. Michael D. Ironside Director of Operations NA
Dr. Jeffrey Norenberg Chief Scientific Officer NA
Dr. Ellen van Dam Ph.D. Head of R&D NA
Mr. Shaemus Gleason Exec. VP of US Operations NA
Dr. Robert M. Miller Ph.D. Consultant Chief Medical Officer 1952
Mr. William Cheadle Financial Controller NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.